Argenx

This study tests if a new medicine, empasiprubart, works as well as standard IVIg for adults with multifocal motor neuropathy (MMN), a condition that causes muscle weakness. About 154 people who have responded to IVIg in the past will receive either empasiprubart or IVIg for up t…

This study looks at the long-term safety of a drug called efgartigimod in children with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. About 12 children who were in earlier studies will continue to receive the drug either through a vein or as a shot…

This study tested a drug called ARGX-119 in 60 adults with ALS to see if it was safe and could slow the disease. The trial was stopped early because early results showed it was unlikely to help patients. The decision was not due to safety concerns, and follow-up visits are still …

This study tests a drug called efgartigimod for adults with ocular myasthenia gravis, a condition that causes eye muscle weakness. Half of the 141 participants get the drug, half get a placebo for 7 weeks, then everyone gets the drug for up to 2 years. The goal is to see if it im…

This study is a long-term follow-up for adults with multifocal motor neuropathy (MMN), a rare condition that causes progressive muscle weakness. It tests the safety and effectiveness of a drug called ARGX-117, given intravenously. Participants who completed an earlier trial can j…

This study tests an experimental drug called ARGX-117 in people who receive a kidney from a deceased donor and are at risk for delayed graft function (when the kidney takes time to start working). About 103 participants will receive either the drug or a placebo, and researchers w…

This study tests a drug called efgartigimod for people with moderate-to-severe primary Sjögren's disease, an autoimmune condition causing dry eyes and mouth. About 631 adults will receive either the drug or a placebo for 48 weeks, followed by an open-label period where everyone g…

This study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases called myositis. People who already took part in a previous study of this drug can join. They will receive the drug for up to 51 months and then be followed for 56 da…

This study tests a drug called efgartigimod given as a shot under the skin for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if long-term use is safe and helps maintain safe pl…

This study tests an investigational drug called efgartigimod given through a vein for adults with generalized myasthenia gravis (gMG) who do not have the usual acetylcholine receptor antibody. The goal is to see if it improves daily activities and muscle strength compared to a pl…

This study tests a new medicine called empasiprubart against a placebo in adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. About 3 participants will receive the drug or placebo for 25 weeks, then be followed for safety over a year. The goal is …

This study follows 413 adults with multifocal motor neuropathy (MMN) over time to learn how the disease progresses and affects daily life. Researchers will collect information on symptoms, quality of life, and healthcare costs during regular doctor visits. No experimental treatme…